A
Argun Akcakanat
Researcher at University of Texas MD Anderson Cancer Center
Publications - 57
Citations - 3084
Argun Akcakanat is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 28, co-authored 48 publications receiving 2474 citations. Previous affiliations of Argun Akcakanat include Niigata University & Mayo Clinic.
Papers
More filters
Journal ArticleDOI
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf,Anne V. Philips,Funda Meric-Bernstam,Na Qiao,Yun Wu,Susan M. Harrington,Xiaoping Su,Ying Wang,Ana M. Gonzalez-Angulo,Argun Akcakanat,Akhil Chawla,Michael Curran,Patrick Hwu,Padmanee Sharma,Jennifer K. Litton,Jeffrey J. Molldrem,Gheath Alatrash +16 more
TL;DR: Using tissue microarrays containing 105 triple-negative breast cancer specimens, Mittendorf and colleagues show that 20% of the TNBC specimens express PD-L1, half have lost PTEN, and inhibitors of PI3K pathway decrease PD- l1 expression, providing a rationale for therapeutic targeting of PD- L1 for TNBC.
Journal ArticleDOI
PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
Funda Meric-Bernstam,Argun Akcakanat,Huiqin Chen,Kim Anh Do,Takafumi Sangai,Farrell Adkins,Ana M. Gonzalez-Angulo,Asif Rashid,Katherine Crosby,Mei Dong,Alexandria T. Phan,Robert A. Wolff,Sanjay Gupta,Gordon B. Mills,James C. Yao +14 more
TL;DR: Rapamycin-mediated Akt activation is greater in RS cells, with a similar observation in patients with clinical responses on exploratory biomarker analysis; thus feedback loop activation of Akt is not a marker of resistance but rather may function as an indicator of rapamycin activity.
Journal ArticleDOI
Targeting the PI3-kinase/Akt/mTOR signaling pathway.
TL;DR: An overview of the PI3K/Akt/mTOR signaling pathway is presented, as a central regulator of cell growth, protein translation, survival, and metabolism, activation of this signaling pathway contributes to the pathogenesis of many tumor types.
Journal ArticleDOI
Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer
Takafumi Sangai,Argun Akcakanat,Huiqin Chen,Emily Tarco,Yun Wu,Kim Anh Do,Todd W. Miller,Carlos L. Arteaga,Gordon B. Mills,Ana M. Gonzalez-Angulo,Funda Meric-Bernstam +10 more
TL;DR: In vitro, MK-2206 showed a synergistic interaction with paclitaxel in MK- 2206–sensitive cell lines, and this combination had significantly greater antitumor efficacy than either agent alone in vivo.
Journal ArticleDOI
Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors
TL;DR: Rapamycin causes significant growth inhibition in carcinoid tumor cell lines in vitro and in vivo, thus mTOR is a promising therapeutic target for neuroendocrine tumors and octreotide does not enhance the efficacy of rapamycin's antiproliferative effects in the models tested.